HC Wainwright Forecasts Xeris Biopharma Q1 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Xeris Biopharma in a note issued to investors on Monday, March 2nd. HC Wainwright analyst B. Folkes forecasts that the company will post earnings of ($0.03) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.41) per share.

A number of other analysts have also issued reports on the company. Oppenheimer reissued an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Barclays started coverage on shares of Xeris Biopharma in a report on Monday, December 8th. They issued an “overweight” rating and a $9.00 target price for the company. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Piper Sandler lifted their price target on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Xeris Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma Price Performance

Shares of NASDAQ:XERS opened at $6.07 on Thursday. The company has a market cap of $1.05 billion, a P/E ratio of -606.39 and a beta of 0.61. The business has a fifty day simple moving average of $7.16 and a 200-day simple moving average of $7.61. Xeris Biopharma has a 52 week low of $3.65 and a 52 week high of $10.08. The company has a quick ratio of 1.35, a current ratio of 2.19 and a debt-to-equity ratio of 16.10.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The firm had revenue of $85.81 million during the quarter, compared to analysts’ expectations of $86.00 million.

Insider Buying and Selling

In related news, insider John Patrick Shannon, Jr. sold 24,907 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $7.08, for a total value of $176,341.56. Following the completion of the sale, the insider directly owned 2,705,346 shares in the company, valued at approximately $19,153,849.68. This represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $6.25, for a total value of $104,168.75. Following the transaction, the insider owned 1,226,507 shares in the company, valued at approximately $7,665,668.75. This represents a 1.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 240,308 shares of company stock valued at $1,732,453. 6.47% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new position in Xeris Biopharma during the 4th quarter worth approximately $25,000. AlphaQuest LLC acquired a new position in shares of Xeris Biopharma during the third quarter worth $35,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Xeris Biopharma by 9,276.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after purchasing an additional 7,421 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Xeris Biopharma by 29.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 2025 earnings beat — Xeris reported EPS of ~$0.0615 vs. ~$0.03 expected, demonstrating the company has moved into profitability and reinforcing near‑term operational momentum. Earnings Call Transcript
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $10 price target and provided multi‑year EPS forecasts (showing progression to positive EPS in FY2026 and continuing growth through FY2030), which supports upside expectations for the stock. HC Wainwright Buy Report
• Positive Sentiment: Analyst consensus shifted to a “Moderate Buy,” adding third‑party confirmation of favorable sentiment around the company’s outlook and execution. Analyst Consensus
• Neutral Sentiment: Bull case commentary — a Seeking Alpha piece argues Xeris is undervalued given its drug portfolio, which can attract longer‑term investors but is opinion‑driven rather than new company data. Seeking Alpha Analysis
• Neutral Sentiment: HC Wainwright trimmed some longer‑term EPS forecasts modestly (FY2026–FY2029 reductions) while keeping a Buy rating and $10 target — a mixed signal that slightly lowers growth assumptions but leaves the analyst stance constructive. MarketBeat Coverage
• Negative Sentiment: Insider sale — director Beth Hecht sold 16,667 shares at an average $6.25; the sale is small relative to total holdings but may be viewed negatively by some investors. SEC filing: Form 4
• Negative Sentiment: Patent litigation risk — coverage highlights ongoing Recorlev patent disputes that could pose legal/financial risks and introduce uncertainty around future product exclusivity and revenue. Yahoo Finance: Patent Battles

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.